BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 8579054)

  • 1. Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea.
    Furgerson JL; Vukelja SJ; Baker WJ; O'Rourke TJ
    Am J Hematol; 1996 Feb; 51(2):137-40. PubMed ID: 8579054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Nand S; Stock W; Godwin J; Fisher SG
    Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Leukemic risk in thrombocythemia].
    Liozon E; Turlure P
    Ann Med Interne (Paris); 1998 Mar; 149(2):82-6. PubMed ID: 11490529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Essential thrombocythemia and acute leukemia.
    Ferrari D; Ticozzelli G; De Vizzi M; Corigliano P; De Vizzi G
    Haematologica; 1993; 78(6):401-2. PubMed ID: 8175035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myelodysplastic transformation in a case of essential thrombocythemia treated with pipobroman.
    Messora C; Bensi L; Vanzanelli P; Temperani P; Carotenuto M; Sacchi S
    Haematologica; 1996; 81(1):51-3. PubMed ID: 8900853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea.
    Bernasconi P; Boni M; Cavigliano PM; Calatroni S; Brusamolino E; Passamonti F; Volpe G; Pistorio A; Giardini I; Rocca B; Caresana M; Lazzarino M; Bernasconi C
    Leukemia; 2002 Oct; 16(10):2078-83. PubMed ID: 12357360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leukemic transformation of polycythemia vera after treatment with hydroxyurea with abnormalities of chromosome 17.
    Tóthová E; Fricová M; Stecová N; Hlebasková M; Kafková A; Raffac S; Guman T; Svorcová E; Nebesnáková E
    Neoplasma; 2001; 48(5):389-92. PubMed ID: 11845984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute promyelocytic leukemia developing in untreated essential thrombocythemia.
    Sato N; Furukawa T; Masuko M; Hashimoto S; Takahashi H; Baba M; Inano K; Suzuki N; Toba K; Fuse I; Aizawa Y
    Am J Hematol; 2002 Oct; 71(2):114-6. PubMed ID: 12353311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leukemia and myelodysplasia in patients with essential thrombocythemia treated with cytotoxic agents.
    Randi ML; Fabris F; Girolami A
    Haematologica; 1999 Nov; 84(11):1049-50. PubMed ID: 10553169
    [No Abstract]   [Full Text] [Related]  

  • 10. [Essential thrombocythemia in transformation from myelodysplastic syndrome to acute myeloid leukemia with inv(3) after treatment for gastric cancer].
    Horikoshi M; Machida U; Itikawa M; Seo S; Masuda S; Kurokawa M; Ogawa S; Sunaga S; Honda H; Aoki K; Chiba S; Mitani K; Hirai H; Yazaki Y
    Rinsho Ketsueki; 2000 Jan; 41(1):68-71. PubMed ID: 10695403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A lower-leg ulcer during hydroxyurea therapy for essential thrombocythemia].
    Iwama H; Kawakubo K; Nehashi Y; Kuriyama Y; Iwase O; Ohyashiki K; Watanabe K; Ebihara Y; Toyama K
    Gan To Kagaku Ryoho; 1996 Jun; 23(7):937-9. PubMed ID: 8678547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Essential thrombocythemia in transformation to acute leukemia (FAB-M0) as a natural history from myelofibrosis with t(1;7)].
    Hayashi S; Iwama H; Uchida Y; Kawakubo K; Inatomi Y; Nagasu M; Miyazawa K; Ohyashiki JH; Ohyashiki K; Toyama K
    Rinsho Ketsueki; 1997 May; 38(5):445-7. PubMed ID: 9194391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gangrene of the toes in a patient with chronic myelogenous leukemia after long-term hydroxyurea therapy.
    Leo E; Krämer A; Hochhaus A; Krasniqi F; Hehlmann R; Ho AD
    Ann Hematol; 2002 Aug; 81(8):467-9. PubMed ID: 12224005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical parameters for determining when and when not to treat essential thrombocythemia.
    Barbui T; Finazzi G
    Semin Hematol; 1999 Jan; 36(1 Suppl 2):14-8. PubMed ID: 9930552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Central nervous system granulocytic sarcoma in a patient with essential thrombocythemia.
    Grande M
    Am J Hematol; 1996 Jan; 51(1):64-7. PubMed ID: 8571939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Drug-induced fever caused by hydroxyurea. Apropos of 3 new cases].
    Gallant C; Vial T; Allochon Y; Monier JM; Blanc M; Evreux JC
    Ann Med Interne (Paris); 1998 Mar; 149(2):59-61. PubMed ID: 11490525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leukemic transformation of essential thrombocythemia without previous cytoreductive treatment.
    Andersson PO; Ridell B; Wadenvik H; Kutti J
    Ann Hematol; 2000 Jan; 79(1):40-2. PubMed ID: 10663620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Essential thrombocythemia and leukemic transformation.
    Sedlacek SM; Curtis JL; Weintraub J; Levin J
    Medicine (Baltimore); 1986 Nov; 65(6):353-64. PubMed ID: 3465986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physician Education: Myelodysplastic Syndrome.
    Yoshida Y
    Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Essential thrombocythemia with ringed sideroblasts: a heterogeneous spectrum of diseases, but not a distinct entity.
    Schmitt-Graeff A; Thiele J; Zuk I; Kvasnicka HM
    Haematologica; 2002 Apr; 87(4):392-9. PubMed ID: 11940483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.